Fumile Completes Pre-A Financing to Accelerate Innovation in Domestic High-End Aesthetic Photonic Devices

VCBeat has learned at the earliest opportunity that a domestic manufacturer of high-end medical aesthetic optoelectronic devicesSuzhou Fumeilei Medical Technology Co., Ltd.(hereinafter referred to as“Fumeilei Medical”) recently announced the completion of a funding round led byVoyong FundLead Investor, Existing ShareholdersMARATHON VENTURE PARTNERSCo-investmentPre-Series AFinancing. It is reported that the funds from this round will be used forR&D Investment, Scale-up and Mass Production, and Market Promotion.

Several months ago, Fumeilei Medical secured tens of millions of yuan in angel-round financing, exclusively invested by MARATHON VENTURE PARTNERS. The company’s ability to close another round of financing in such a short period, while earning strong recognition from both new and existing shareholders, clearly demonstrates the favor it enjoys in the capital market.(For reference:【Exclusive】Fumeilei Medical Secures Tens of Millions in Angel Funding from MARATHON VENTURE PARTNERS, Accelerating the Localization of High-End Medical Aesthetic Devices）

As a new entrant in the field of medical aesthetic optoelectronic devices, Fumeilei Medical, established in September 2021, positions its products in the research, development, and manufacturing of mid-to-high-end optoelectronic devices, aspiring to become a global leader in medical aesthetic optoelectronic equipment.

The core founding team hails from Peking University and prestigious overseas universities, with years of deep engagement in the medical aesthetics and energy-based device industry. They possess robust technical expertise and profound industry insights. R&D personnel account for two-thirds of the company’s workforce.

Looking at the domestic market, nearly all mid-to-high-end medical aesthetic energy-based devices used by compliant medical aesthetic institutions in China are imported products, with import manufacturers holding an overall market share of over 80% in the regulated domestic market. Previously constrained by high technical barriers, domestically produced devices were mostly concentrated in the low- to mid-end product segments.

As the medical aesthetics market continues to expand, the high cost of compliant imported equipment has become an unbearable burden for many small and medium-sized medical aesthetics institutions, thereby fostering gray-market activities such as the trade of smuggled and counterfeit devices and illegal leasing. Medical aesthetic accidents caused by the use of smuggled or counterfeit equipment are all too common; what was intended to enhance beauty and well-being for patients has instead turned into fatal disfigurement.

From the very beginning, the Fumeilei Medical team has prioritized the safety and efficacy of its products as the foremost imperative for corporate development, aiming to establish “Fumeilei” as a synonym for safety and effectiveness.

In the year-plus since its establishment, Fumeilei Medical has made rapid progress in innovative R&D and product commercialization. The company’s core productsForePico Multi-Wavelength Picosecond Laser Treatment DeviceRegistration testing has been officially launched recently, and the actual performance parameters of the product are in no way inferior to those of imported counterparts.

ForePico Product Image

Earlier this year, Fumeilei Medical's self-developedNew Generation Intelligent Hydro-Lifting DeviceThe registration application has been formally submitted, and the quality management system assessment for medical devices has been completed; official market approval is expected in the near future.

Meanwhile,Product Pipeline Including Long-Pulse-Width Laser Therapy DevicesPrototype development has also been completed, and the product is about to enter the testing and certification process.

Patents are the cornerstone of development for technology-driven enterprises. To date, Fumeilei Medical has secured four granted patents, with four additional invention patents under substantive examination, demonstrating robust innovation momentum.

The convergence of multidimensional, overlapping foundational capabilities—medical-engineering integration driven by genuine clinical needs, professional expertise emphasizing source innovation, the founding team’s profound industry insights, advantages in compliance and market access, and extensive resource channels—has become the strength and momentum propelling Fumeilei Medical forward.

As consumers of medical aesthetics deepen their scientific understanding, future photoelectric skin treatments will become increasingly precise and refined. The medical aesthetics market will ultimately return to a rational state where “proven efficacy replaces conceptual marketing.” Fumeilei Medical is committed to enabling more beauty seekers to truly experience high-quality, ultra-safe photoelectric products and services in the field of medical aesthetics.

Regarding this financing round,Xia Yuqing, Founder of Fumeilei MedicalHe stated: “We sincerely thank both new and existing shareholders for their recognition and support. Over the past year, Fumeilei Medical has navigated numerous challenges yet still achieved remarkable results. For a startup, every step—from R&D to pilot production, and from technology transfer to mass production—presents significant tests and demands tremendous effort from the Fumeilei team. We remain committed to our original mission in establishing Fumeilei Medical: to diligently craft high-quality products that inspire trust in everyone who encounters our brand.”

Voyong FundHe stated, “Fumeilei Medical’s team has accumulated extensive expertise across the entire industry chain of medical aesthetic optoelectronic devices. They possess not only profound industry insights but also unique product definition capabilities, which are rare to find. In the consumer market, the boom period for medical aesthetic optoelectronic treatments has arrived. Amidst the rising tide of domestic brands, Fumeilei Medical, with its unwavering commitment to regulatory compliance, safety, and efficacy as the core of its products, is poised to become an industry leader.”

MARATHON VENTURE PARTNERS“The high-end medical aesthetic optoelectronic equipment sector represents a high-certainty track for rapid growth over the next decade, offering a triple opportunity for compliance upgrades, domestic substitution, and source innovation, coinciding with a rare market window. With years of deep engagement in the medical aesthetics industry, Fumeilei Medical possesses profound industrial insights and comprehensive core capabilities spanning R&D, regulatory registration, and commercialization, positioning it to become a benchmark for emerging Chinese high-end medical aesthetic optoelectronic brands. Within less than a year following MARATHON VENTURE PARTNERS’ angel investment, the Fumeilei team demonstrated exceptional industry expertise, learning agility, and execution capability, achieving rapid progress in team building and product development. Consequently, we chose to make an oversubscribed investment in the Pre-A round to continue our support.”